Jazz Pharmaceuticals' lung cancer drug Zepzelca failed to meet the primary endpoint of its Phase III confirmatory trial.

The treatment fell short on overall survival in the second-line treatment of relapsed metastatic small cell lung cancer, putting the drug's accelerated approval in that indication at risk.

The failure comes from the Lagoon trial, a Phase III study sponsored by Jazz's partner PharmaMar and conducted across more than 200 sites globally.¹ The results do not affect Zepzelca's full approval in the first-line maintenance setting, which rests on a separate trial, but the company says it has shared the findings with FDA and will discuss next steps regarding post-marketing requirements tied to the second-line accelerated approval.¹

Following the announcement, Jazz shares fell nearly 2% in premarket trading with the company saying the results do not impact its 2026 financial guidance.²

What did the Lagoon trial show?

The Lagoon trial enrolled 724 patients with Second-Line Small Cell Lung Cancer (SCLC) whose disease had progressed following prior platinum-based chemotherapy and randomized them 1:1:1 across three arms: Zepzelca monotherapy at 3.2 mg/m², Zepzelca at a reduced dose in combination with irinotecan, and investigators' choice of topotecan or irinotecan as the control.²

Neither investigational arm met the primary endpoint of overall survival, and patients treated with Zepzelca monotherapy lived a median of 8.7 months, while those in the combination arm lived 10.9 months, compared with 10.7 months in the control group.²

The hazard ratios were 1.190 for Zepzelca monotherapy versus control and 0.902 for the combination versus control, neither statistically significant.

A complicating factor of the results was the Lagoon trial's broader patient population compared to the Phase II pivotal study that originally supported the accelerated approval. Lagoon enrolled patients with a history of Central Nervous System (CNS) involvement, a group that fared notably worse on Zepzelca monotherapy, with a median overall survival of 7.1 months versus 10.3 months in the control arm.²

In the subset without CNS metastases, efficacy was more comparable to the control, though that arm also outperformed historical precedent, making it a more difficult comparator than anticipated.²

On the safety side, treatment-related adverse events were 78.5% with Zepzelca monotherapy and 35% for Grade three or higher events, compared with 93.8% and 64.4% respectively in the control arm, a favorable tolerability profile, though not sufficient to rescue the efficacy finding. No new safety signals were identified.²

What happens to Zepzelca's approval now?

The trial failure puts Zepzelca's accelerated approval for second-line SCLC under scrutiny. FDA's accelerated approval pathway requires sponsors to confirm clinical benefit through post-marketing trials, and the Lagoon results represent that confirmatory effort. Jazz says it will engage with FDA on next steps, but did not indicate whether a voluntary withdrawal or label change is expected.²

Lagoon trial results are entirely separate from the IMforte trial, which underpinned Zepzelca's full approval in October 2025 as a first-line maintenance treatment in combination with Roche's immunotherapy atezolizumab for patients with extensive-stage SCLC whose disease has not progressed after initial chemotherapy. That trial showed Zepzelca reduced the risk of disease progression or death by 46% and the risk of death by 27% compared with atezolizumab alone data that remains unaffected by the Lagoon outcome.²

"Relapsed SCLC is an aggressive cancer with a poor prognosis and patients continue to need treatment options," said Rob Iannone, MD, MSCE, executive vice president, global head of research and development, and chief medical officer of Jazz Pharmaceuticals. "Zepzelca is an important treatment in SCLC and, based on the strength of the IMforte trial results, we believe its most beneficial use is in the first-line maintenance setting in combination with immunotherapy given the rapid progression of metastatic SCLC after first-line chemotherapy induction."

Sources

1. Jazz Pharmaceuticals lung cancer drug fails main trial goal Reuters June 12, 2026 https://www.reuters.com/business/healthcare-pharmaceuticals/jazz-pharmaceuticals-lung-cancer-drug-fails-main-trial-goal-2026-06-12/
2. Jazz Pharmaceuticals Provides Update on Zepzelca (lurbinectedin) Phase III Lagoon Trial in Second-Line Small Cell Lung Cancer Jazz Pharmaceuticals June 12, 2026 https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-provides-update-on-zepzelca-lurbinectedin-phase-3-lagoon-trial-in-second-line-small-cell-lung-cancer-302798651.html